Chemoradiotherapy

Where the papers sit

14 papers from the last 6 months study chemoradiotherapy directly · updated from PubMed 1 Nov 2026

• Response Modifiers in Locally Advanced Cancer

  Checkpoint blockade is moving into concurrent or consolidation treatment with chemoradiotherapy, including durvalumab, pembrolizumab, and ociperlimab plus tislelizumab. Lymphopenia and weight loss repeatedly identify patients with poorer outcomes despite treatment or nutritional support. Hyperthermia offers a nonimmune sensitization strategy through reduced c-Myc/WSB1/β-catenin signaling in cervical cancer. Whether these additions improve survival consistently across lung, head and neck, and cervical cancers remains unresolved.

  5 papers · 35.7%

• Response Prediction in Rectal Cancer

  MRI and FDG-PET/CT are being paired with radiomics and gut microbiome profiles to predict response before or after neoadjuvant treatment. Disease-free survival and decision-curve analyses are moving these markers toward clinical risk stratification. Irinotecan intensification is being tested alongside biomarker-guided treatment selection. The open question is whether these signals can reliably identify patients who need escalation or can avoid unnecessary therapy.

  4 papers · 28.6%

• Others — Cancer Treatment Sequencing and Outcomes

  Treatment sequencing and the added value of radiation are being compared across gastrointestinal, pancreatic, glioma and rare thoracic cancers. Induction or perioperative chemotherapy, preoperative chemoradiotherapy, adjuvant chemoradiotherapy and vorasidenib pretreatment represent distinct disease-specific strategies. Survival, response, metastasis and long-term outcome remain the recurring endpoints. The evidence is too heterogeneous to support one shared treatment direction.

  5 papers · 35.7%